Together, our data demonstrated that Neogenin interacts with Merlin to inhibit tumor malignancy by obstructing EMT progress, and the lack of Neogenin/Merlin is associated with the poorest prognosis in CRC and glioma patients. Here, NEO1 is linked to neoplasm.